Lyell Immunopharma (NASDAQ:LYEL – Free Report) had its target price lowered by Bank of America from $9.00 to $6.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
Separately, HC Wainwright reissued a neutral rating and set a $1.00 price target (down from $6.00) on shares of Lyell Immunopharma in a research note on Thursday.
Lyell Immunopharma Stock Performance
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, sell-side analysts forecast that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC bought a new position in Lyell Immunopharma during the 4th quarter worth approximately $31,000. RPO LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter worth $38,000. Public Employees Retirement System of Ohio boosted its position in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after buying an additional 14,229 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Lyell Immunopharma by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after acquiring an additional 22,701 shares during the last quarter. Finally, Simplicity Wealth LLC purchased a new position in shares of Lyell Immunopharma in the first quarter valued at about $58,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.
About Lyell Immunopharma
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Articles
- Five stocks we like better than Lyell Immunopharma
- What is the Shanghai Stock Exchange Composite Index?
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.